Analytical Data
-
Gene name
CYP17A1
- Application
-
Alternative Names
CYP17A1；CYP17；S17AH；Steroid 17-alpha-hydroxylase/17.20 lyase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05093
-
Expression Region
1-508aa
-
AA Sequence
MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST
-
Molecular Weight
84.4kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP17A1, a key enzyme in steroidogenesis, catalyzes the conversion of pregnenolone and progesterone into androgens, playing a crucial role in sex steroid biosynthesis. This enzyme's activity is pivotal in the production of testosterone and estradiol, with implications for reproductive health, adrenal function, and certain diseases, including hormone-related cancers. Aberrations in CYP17A1 function can lead to various disorders, such as congenital adrenal hyperplasia and polycystic ovary syndrome. The potential for CYP17A1 as a therapeutic target for these conditions and androgen-dependent tumors, like prostate cancer, has spurred significant research interest. Recombinant CYP17A1 protein studies aim to elucidate its mechanistic role in steroid pathways, enabling the development of specific inhibitors for clinical applications. Understanding the structural and functional dynamics of CYP17A1 through recombinant protein expression can also facilitate the design of novel pharmacological agents. Consequently, research into CYP17A1 continues to be of paramount importance to both basic science and therapeutic innovation in endocrinology and oncology.
